Regulatory status is not a safety finding, and medical claims have their own bar

How it works

EPA’s approach to nanoscale materials includes an information-gathering rule and premanufacture notification, both of which are mechanisms for the agency to receive and review information. FDA publishes guidance on whether a regulated product involves nanotechnology and on nanomaterials in cosmetics and in drug products, which tells sponsors what the agency expects to see — again, a process. For medical applications the distinction that matters most to a reader is the one between a laboratory finding, a clinical result in people, and an approved product. Maha keeps those three separate and does not bridge them. We give no treatment advice and make no claim about any therapy.

A concrete case

A press release says a nanoparticle formulation is “FDA-compliant” after a premarket submission. Compliance with a submission requirement is not authorisation, and an in-vitro or animal result cited beside it is not clinical evidence.

Questions worth asking

• Ask precisely which status is being claimed: reported, notified, reviewed, cleared, approved — and for which product and use.
• For a medical claim, ask whether the evidence is in vitro, in animals, in a clinical trial, or in an approved label.
• Ask whether the cited regulatory document is guidance, a rule, or a decision about this product.

Sources

• EPA — Control of Nanoscale Materials under the Toxic Substances Control Act ↗

  EPA treats many nanoscale materials as chemical substances under TSCA, notes that the same substance at the nanoscale may behave differently, and describes a regulatory approach that includes an information-gathering reporting rule and premanufacture notification for new nanoscale materials.

  Boundary: Reporting or review under TSCA is a regulatory process, not a finding that a material is safe, effective or approved for a use.

  Locator, anchor and reuse basis

  Read at: Nanoscale Materials; Regulatory Approach; Information gathering rule; Reporting under the rule. Inspected 2026-09-19. Original paraphrase and link only.

  Verify by searching the source for: regarded as “chemical substances” under the Toxic Substances Control Act. If that phrase is not there, or does not carry the meaning stated above, this citation is wrong and we want to know.

• FDA — Nanotechnology Guidance Documents ↗

  FDA publishes product-category guidance on whether a regulated product involves nanotechnology and on nanomaterials in cosmetics and drug products, rather than a single approval pathway for “nanotechnology”.

  Boundary: Guidance describes FDA’s current thinking for sponsors. It is not a product approval, a clinical finding, or a statement that any marketed nanomaterial product is safe or effective.

  Locator, anchor and reuse basis

  Read at: List of guidance documents, including “Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology”, “Safety of Nanomaterials in Cosmetic Products”, and “Drug Products, Including Biological Products, that Contain Nanomaterials” — each listed as final guidance. Inspected 2026-09-20. Original paraphrase and link only; guidance documents are not reproduced here.

  Verify by searching the source for: Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology. If that phrase is not there, or does not carry the meaning stated above, this citation is wrong and we want to know.

Continue

• What an exposure or safety study does and does not settle
• Reading a nanomaterial datasheet or demonstration claim